Global Information
회사소개 | 문의 | 위시리스트

항생제 내성 시장 : 치료제(병원체별, 치료 유형별), 상황 분석, 경영진, 투자자, 컨설턴트 가이드, 주목 기업 리스트

Antibiotic Resistance Markets - Therapeutics. By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization 2020 to 2024

리서치사 Howe Sound Research
발행일 2019년 11월 상품 코드 616480
페이지 정보 영문 411 Pages
가격
US $ 6,995 ₩ 8,245,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 10,495 ₩ 12,371,000 PDF by E-mail (Five User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 5대의 PC에서만 이용할 수 있는 라이선스로 인쇄가 불가능합니다.
US $ 13,995 ₩ 16,497,000 PDF by E-mail (Enterprise License) help
동일기업 내 모든 분들이 이용할 수 있는 라이선스입니다. 편집 및 인쇄는 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



항생제 내성 시장 : 치료제(병원체별, 치료 유형별), 상황 분석, 경영진, 투자자, 컨설턴트 가이드, 주목 기업 리스트 Antibiotic Resistance Markets - Therapeutics. By Pathogen and Therapy Type. With Situation Analysis, Executive & Investor Guides & Customization 2020 to 2024
발행일 : 2019년 11월 페이지 정보 : 영문 411 Pages

항균제 내성(Antimicrobial Resistance)은 새로운 감염을 생성하고 있으며, 현재의 항생제 의료에 대한 내성을 가진 "슈퍼버그"가 탄생했습니다. 이 성장 시장을 파악하기 위해 신기술( 및 신약)이 개발중입니다.

세계의 항생제 내성(Antibiotic Resistance) 시장에 대해 조사했으며, 시장의 현황과 향후 동향, 성장 기회, 지역별 동향, 시장 참여 기업의 개요에 대해 정리하여 전해드립니다.

제1장 서론과 시장의 정의

  • 큰 위협과 기회
  • 기회의 정의
  • 방법과 소스
  • 미국 시장 전망

제2장 동적 시장의 개요

  • 시장 참여 기업 : 역할과 영향
  • 항균 내성의 이해
  • 새로운 항생제·기술로의 길
  • 항균 내성에서 진단의 주요 역할

제3장 시장 기회

  • 큰 시장 기회
  • 치료 기술 개발 기회
  • 최근 발전

제4장 바이오테크놀러지 기업과 기술

  • 치료제
  • 치료 경주

제5장 국가별 시장 규모 : 북미

  • 미국
  • 캐나다

제6장 국가별 시장 규모 : 유럽

  • 프랑스
  • 독일
  • 영국
  • 스페인
  • 이탈리아
  • 러시아
  • 기타 유럽 및 구소련방

제7장 국가별 시장 규모 : 아시아태평양

  • 중국
  • 일본
  • 한국
  • 인도
  • 호주
  • 기타

제8장 국가별 시장 규모 : 라틴아메리카, 아프리카, 중동

  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 아프리카·중동

제9장 세계 시장 요약

  • 시장 요약
    • 병원체별
    • 기술 기회별

제10장 향후 동향

KSA 19.10.30

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Table of Tables

  • Table 1 USA - Outpatient Use of Antibiotics by Class
  • Table 2 USA - Outpatient Use of Antibiotics Top 5
  • Table 3 Market Players by Type
  • Table 4 Known Human Pathogenic Diseases
  • Table 5 The Key Market Opportunities
  • Table 6 - Market Potential DRSP Therapeutic
  • Table 7 - Market Potential DRC Therapeutic
  • Table 8 Eight Technologies under development
  • Table 9 Antibodies Approved for Infectious Disease Treatment
  • Table 10 Therapeutic Technology Research - # of Companies
  • TABLE 11 GLOBAL MARKET BY COUNTRY
  • TABLE 12 GLOBAL MARKET BY PATHOGEN
  • TABLE 13 GLOBAL MARKET BY TECHNOLOGY
  • TABLE 14 DRSP SEGMENT BY COUNTRY
  • TABLE 15 DRC SEGMENT BY COUNTRY
  • TABLE 16 CD SEGMENT BY COUNTRY
  • TABLE 17 MRSA SEGMENT BY COUNTRY
  • TABLE 18 DRNG SEGMENT BY COUNTRY
  • TABLE 19 DRNTS SEGMENT BY COUNTRY
  • TABLE 20 OTHER PATHOGEN SEGMENT BY COUNTRY
  • TABLE 21 ANTIBIOTICS SEGMENT BY COUNTRY
  • TABLE 22 PHAGE SEGMENT BY COUNTRY
  • TABLE 23 PEP/LYS SEGMENT BY COUNTRY
  • TABLE 24 ANTIBODIES SEGMENT BY COUNTRY
  • TABLE 25 VACCINE SEGMENT BY COUNTRY
  • TABLE 26 OTHER TECHNOLOGY SEGMENT BY COUNTRY
  • Table 27 2011 to 2015 Top Selling Drugs

Table of Figures

  • Figure 1 Pharmaceutical Spending Trends
  • Figure 2 AMR and Antibiotic Introduction
  • Figure 3 The Death Toll of AMR
  • Figure 4 Phage T4 Anatomy and Infection Cycle
  • Figure 5 Key Global Markets
  • FIGURE 6 PATHOGEN SHARE BY YEAR
  • FIGURE 7 PATHOGEN SEGMENT GROWTH RATES
  • FIGURE 8 SEGMENT SHARE SHIFTS
  • Figure 9 Market Share Start Year
  • Figure 10 Market Share End Year
  • FIGURE 11 TECHNOLOGY SHARE BY YEAR
  • FIGURE 12 PATHOGEN SEGMENT GROWTH RATES
  • FIGURE 13 SEGMENT SHARE SHIFTS
  • Figure 14 Market Share Start Year
  • Figure 15 Market Share End Year
  • FIGURE 16 DRSP VS. TOTAL MARKET GROWTH
  • FIGURE 17 DRC VS. TOTAL MARKET GROWTH
  • FIGURE 18 CD VS. TOTAL MARKET GROWTH
  • FIGURE 19 MRSA VS. TOTAL MARKET GROWTH
  • FIGURE 20 DRNG VS. TOTAL MARKET GROWTH
  • FIGURE 21 DRNTS VS. TOTAL MARKET GROWTH
  • FIGURE 22 OTHER PATHOGEN VS. TOTAL MARKET GROWTH
  • FIGURE 23 ANTIBIOTICS VS. TOTAL MARKET GROWTH
  • FIGURE 24 PHAGE VS. TOTAL MARKET GROWTH
  • FIGURE 25 PEP/LYS VS. TOTAL MARKET GROWTH
  • FIGURE 26 ANTIBODIES VS. TOTAL MARKET GROWTH
  • FIGURE 27 VACCINE VS. TOTAL MARKET GROWTH
  • FIGURE 28 OTHER TECHNOLOGY VS. TOTAL MARKET GROWTH

OVERVIEW:

Antimicrobial Resistance is creating new kinds of infections and “superbugs” that are resistant to current antibiotic medicines. New technologies (and new drugs) are under development to capture this growing market. We have identified the 6 Key Large Opportunities in this space and developed market forecasts. We have looked at the technology picture too, giving you, plain language understanding of the different ways pathogens, and infections, can be treated, including an explanation of the key role diagnostics will play. This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report. And we summarize what technologies they are using.

Our research makes you the expert in your organization. Get our research team working for you by ordering all, or a portion, of this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance, and additional specific data, is provided without additional charges.

All report data is available in Excel format on request.

Make investment decisions and valuations with confidence using the latest data.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

i. Antimicrobial Resistance - Strategic Situation Analysis

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

  • 1.1 The Growing Threat and Opportunity of Antimicrobial Resistance
  • 1.2 Defining the Opportunity
    • 1.2.1 Revenue Market Size
  • 1.3 Methods and Sources
    • 1.3.1 Authors
    • 1.3.2 Sources
  • 1.4 U.S. Antibiotic Markets - Perspective
    • 1.4.1 U.S. Outpatient Use of Antibiotics
    • 1.4.2 U.S. Pharmaceutical Spending

2. Overview of a Dynamic Market

  • 2.1 Market Players - Roles & Impacts
    • 2.1.1 Drug manufacturers - Larger/pharmaceutical
    • 2.1.2 Drug manufacturers - Generic
    • 2.1.3 Contract Research and Manufacturing
    • 2.1.4 In Vitro Diagnostics Industry
    • 2.1.5 Drug Marketing Companies
    • 2.1.6 Biotechnology Companies
    • 2.1.7 Regulatory Bodies
  • 2.2 Understanding Antimicrobial Resistance
    • 2.2.1 What is Antimicrobial Resistance (AMR)
    • 2.2.2 Bacteria and Other Microbes
    • 2.2.3 The History of Antibiotics
    • 2.2.4 The Role of Animal Husbandry
    • 2.2.5 The Implications of Horizontal Transfer
    • 2.2.6 The Threat of AMR
  • 2.3 The Changing Road to New Antibiotics & Technologies
  • 2.4 The Key Role of Diagnostics in AMR

3. The Market Opportunity of AMR

  • 3.1 The Key Large Market Opportunities in AMR
    • 3.1.1 Streptococcus Pneumoniae (DRSP)
    • 3.1.2 Campylobacter (DRC)
    • 3.1.3 Clostridium Difficile (CD)
    • 3.1.4 Staphylococcus aureus (MRSA)
    • 3.1.5 Neisseria gonorrhoeae (DRNG)
    • 3.1.6 Salmonella (DRNTS)
  • 3.2 Therapeutic Technology Development Opportunities
    • 3.2.1 Using Viruses Against Bacteria
    • 3.2.2 Hydrolytic Enzymes Join the Fight
    • 3.2.3 Antibodies
    • 3.2.4 Vaccines
    • 3.2.5 Probiotic Technology
    • 3.2.6 Peptides vs. Pathogens
    • 3.2.7 Mining Obsolete Science
    • 3.2.8 CRISPR Antibiotics
  • 3.3. Antibiotic Resistance Recent Developments
    • 3.3.1 Recent Developments - Importance and How to Use This Section
    • 3.3.2 Importance of These Developments
    • 3.3.3 How to Use This Section
      • New class of antibiotics for AMR
      • New AMR Drug
      • CRISPR Modifies Phages to target Superbugs
      • Genetically Modified Phage Fights 'Superbug' Infection
      • NIH awards $33 million grant to develop new antibiotics
      • Bacteria found in ancient Irish soil halts growth of superbugs
      • OpGen Partners With NYS DOH, Merck Subsidiary for AMR Surveillance
      • New breakthrough in the war against antibiotic resistance
      • Amicrobe, Inc., patents AMR Gel
      • Microneedle Patch to Combat AMR
      • Antimicrobial peptides find application medium
      • Antibiotic shortages fuelling antimicrobial resistance

4. Key Biotechnology Companies and Their Technology

  • 4.2 Therapeutics
    • 4.2.1 The Medicines Company
    • 4.2.2 Melinta Therapeutics
    • 4.2.3 Arsanis
    • 4.2.4 Phage Technologies S.A
    • 4.2.5 Westway Health
    • 4.2.6 Tetraphase Pharmaceuticals
    • 4.2.7 BioVersys GmbH
    • 4.2.8 Nabriva Therapeutics
    • 4.2.9 Macrolide Pharmaceuticals
    • 4.2.10 Nemesis Bioscience
    • 4.2.11 C3J Therapeutics, Inc
    • 4.2.12 EpiBiome
    • 4.2.13 discuva
    • 4.2.14 SmartPhage
    • 4.2.15 AmpliPhi Biosciences
    • 4.2.16 Pherecydes Pharma
    • 4.2.17 Micreos
    • 4.2.18 Procarta Biosystems
    • 4.2.19 Lumavita
    • 4.2.20 Madam Therapeutics
    • 4.2.21 Priaxon
    • 4.2.22 Biolytx Pharmaceuticals
    • 4.2.23 AntibioTx
    • 4.2.24 Xellia Pharmaceuticals
    • 4.2.25 Paratek Pharmaceuticals
    • 4.2.26 Synereca Pharmaceuticals
    • 4.2.27 Allecra Therapeutics
    • 4.2.28 Fixed Phage
    • 4.2.29 Enanta Pharmaceuticals, Inc
    • 4.2.30 Demuris
    • 4.2.31 Prommune
    • 4.2.32 Biosergen
    • 4.2.33 Innovation Pharmaceuticals
    • 4.2.34 Aviragen Therapeutics
    • 4.2.35 Achillion Pharmaceuticals
    • 4.2.36 ImmunNovative Developments, S.L.
    • 4.2.37 Achaogen, Inc
    • 4.2.38 SelectX Pharmaceuticals, Inc.
    • 4.2.39 TaiGen Biotechnology Co., Ltd
    • 4.2.40 Theravance Biopharma
    • 4.2.41 Abbvie
    • 4.2.42 KYORIN Pharmaceutical Co.,Ltd.
    • 4.2.43 Iterum Therapeutics Limited
    • 4.2.44 Forge Therapeutics
    • 4.2.45 Alopexx Vaccine LLC
    • 4.2.46 Integrated Biotherapeutics
    • 4.2.47 Hennepin Life Sciences
    • 4.2.48 Fedora Pharmaceuticals Inc
    • 4.2.49 Contrafect Corporation
    • 4.2.50 Basilea Pharmaceutica Ltd.
    • 4.2.51 AiCuris
    • 4.2.52 RedHill Biopharma
    • 4.2.53 Redx Pharma Plc/ Redx Anti Infectives Ltd.
    • 4.2.54 ABAC Therapeutics
    • 4.2.55 Alaxia SAS
    • 4.2.56 Antabio S.A.S
    • 4.2.57 Auspherix Ltd
    • 4.2.58 BioFilm Pharma
    • 4.2.59 Centauri Therapeutics Ltd
    • 4.2.60 Combioxin SA
    • 4.2.61 Da Volterra
    • 4.2.62 Debiopharm International SA
    • 4.2.63 Deinobiotics/Deinove
    • 4.2.64 Destiny Pharma plc
    • 4.2.65 Eligo Bioscience
    • 4.2.66 Helperby Therapeutics Ltd
    • 4.2.67 Karveel Pharmaceuticals
    • 4.2.68 MaaT Pharma
    • 4.2.69 Motif BioSciences, Inc / Motif Bio PLC
    • 4.2.70 Mutabilis SAS
    • 4.2.71 Neem Biotech Ltd
    • 4.2.72 Northern Antibiotics Oy (Ltd)
    • 4.2.73 Nosopharm
    • 4.2.74 NovaBiotics Ltd
    • 4.2.75 Phico Therapeutics Ltd
    • 4.2.76 Polyphor Ltd
    • 4.2.77 QureTech Bio AB
    • 4.2.78 SetLance srl
    • 4.2.79 Ultupharma AB
    • 4.2.80 Vaxdyn
    • 4.2.81 Vibiosphen
    • 4.2.82 Bioaster
    • 4.2.83 Vivexia
    • 4.2.85 KBP Biosciences
    • 4.2.86 Absynth Biologics
    • 4.2.87 Spero Therapeutics
    • 4.2.88 Merck
    • 4.2.89 Symphogen
    • 4.2.90 Warp Drive Bio
    • 4.2.91 Johnson & Johnson (Janssen)
    • 4.2.92 Pfizer
    • 4.2.93 Allergan
    • 4.2.95 Novartis
    • 4.2.97 AstraZeneca
    • 4.2.100 Cipla
    • 4.2.101 DSM Sinochem Pharmaceuticals
    • 4.2.102 Wockhardt Ltd.
    • 4.2.103 VenatoRx Pharmaceuticals
    • 4.2.104 MicuRx
    • 4.2.105 Entasis Therapeutics
    • 4.2.106 Merlion Pharmaceuticals
    • 4.2.107 Aridis Pharmaceuticals Inc
  • 4.3 The Therapeutics Race - Summary of Companies Research Areas

5. Global Market Size

  • 5.1 Global Market by Country
  • 5.2 Global Market by Pathogen
  • 5.3 Global Market by Technology

7. Market Sizes by Pathogen

  • 7.1 DRSP Market
  • 7.2 DRC Market
  • 7.3 CD Market
  • 7.4 MRSA Market
  • 7.5 DRNG Market
  • 7.6 DRNTS Market
  • 7.7 Other Pathogen Market

8. Market Sizes by Technology

  • 8.1 Antibiotics Market
  • 8.2 Phage Market
  • 8.3 Pep/Lys Market
  • 8.4 Antibodies Market
  • 8.5 Vaccine Market
  • 8.6 Other Technology Market

9. The Future of AMR

Appendices

  • I. United States Medicare System: Top Selling Drugs 2011-2015
Back to Top
전화 문의
F A Q